Teva Pharmaceutical Industries (BSP:T1EV34) Piotroski F-Score: 7 (As of Jul. 01, 2026) — 40% Above Median


BSP:T1EV34 Teva Pharmaceutical Industries Ltd BSP:T1EV34
60 GF Score
Price R$85.99
GF Value R$53.85
! 4 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Piotroski F-Score?

Teva Pharmaceutical Industries BSP:T1EV34 60 Piotroski F-Score is 7 as of Jul. 01, 2026, which is 40% above its 10-year median of 5.00. GuruFocus rates BSP:T1EV34 with a GF Score™ of 60/100 and a GF Value™ of R$53.85. The stock has 4 warning signs investors should review. Among 979 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks better than 91.83% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Teva Pharmaceutical Industries has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Teva Pharmaceutical Industries's Piotroski F-Score or its related term are showing as below:

BSP:T1EV34' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Teva Pharmaceutical Industries was 8. The lowest was 2. And the median was 5.

Teva Pharmaceutical Industries  (BSP:T1EV34) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Teva Pharmaceutical Industries Piotroski F-Score Related Terms


Teva Pharmaceutical Industries Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Piotroski F-Score Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 3.00 5.00 5.00 8.00

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 6.00 7.00 8.00 7.00

BSP:T1EV34 vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Piotroski F-Score falls into.


BSP:T1EV34
60GF Score
Teva Pharmaceutical Industries Ltd BSP:T1EV34
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 1563.916 + 2322.179 + 2618.736 + 1929.722 = R$8,435 Mil.
Cash Flow from Operations was 1258.897 + 1978.947 + 6317.701 + -209.184 = R$9,346 Mil.
Revenue was 23159.261 + 24026.24 + 25701.803 + 20819.038 = R$93,706 Mil.
Gross Profit was 11657.272 + 12356.352 + 14490.339 + 10312.771 = R$48,817 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(221197.411 + 222558.5 + 213747.728 + 222308.864 + 209393.184) / 5 = R$217841.1374 Mil.
Total Assets at the begining of this year (Mar25) was R$221,197 Mil.
Long-Term Debt & Capital Lease Obligation was R$74,757 Mil.
Total Current Assets was R$71,698 Mil.
Total Current Liabilities was R$70,767 Mil.
Net Income was -4556.641 + -2420.019 + -1323.917 + 1232.233 = R$-7,068 Mil.

Revenue was 22427.72 + 23989.75 + 25801.129 + 22404.767 = R$94,623 Mil.
Gross Profit was 10901.466 + 11895.194 + 12940.221 + 10807.954 = R$46,545 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(213000.985 + 222650.602 + 231247.452 + 239927.926 + 221197.411) / 5 = R$225604.8752 Mil.
Total Assets at the begining of last year (Mar24) was R$213,001 Mil.
Long-Term Debt & Capital Lease Obligation was R$95,112 Mil.
Total Current Assets was R$66,379 Mil.
Total Current Liabilities was R$64,243 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Teva Pharmaceutical Industries's current Net Income (TTM) was 8,435. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Teva Pharmaceutical Industries's current Cash Flow from Operations (TTM) was 9,346. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=8434.553/221197.411
=0.03813134

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-7068.344/213000.985
=-0.03318456

Teva Pharmaceutical Industries's return on assets of this year was 0.03813134. Teva Pharmaceutical Industries's return on assets of last year was -0.03318456. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Teva Pharmaceutical Industries's current Net Income (TTM) was 8,435. Teva Pharmaceutical Industries's current Cash Flow from Operations (TTM) was 9,346. ==> 9,346 > 8,435 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=74757.132/217841.1374
=0.3431727

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=95112.296/225604.8752
=0.42158795

Teva Pharmaceutical Industries's gearing of this year was 0.3431727. Teva Pharmaceutical Industries's gearing of last year was 0.42158795. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=71697.816/70766.947
=1.01315401

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=66379.377/64243.122
=1.03325266

Teva Pharmaceutical Industries's current ratio of this year was 1.01315401. Teva Pharmaceutical Industries's current ratio of last year was 1.03325266. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Teva Pharmaceutical Industries's number of shares in issue this year was 2358. Teva Pharmaceutical Industries's number of shares in issue last year was 2318. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=48816.734/93706.342
=0.52095443

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=46544.835/94623.366
=0.49189579

Teva Pharmaceutical Industries's gross margin of this year was 0.52095443. Teva Pharmaceutical Industries's gross margin of last year was 0.49189579. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=93706.342/221197.411
=0.42363218

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=94623.366/213000.985
=0.4442391

Teva Pharmaceutical Industries's asset turnover of this year was 0.42363218. Teva Pharmaceutical Industries's asset turnover of last year was 0.4442391. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Teva Pharmaceutical Industries has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Teva Pharmaceutical Industries (BSP:T1EV34) has a Piotroski F-Score of 7 as of Jul. 01, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Teva Pharmaceutical Industries and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, Teva Pharmaceutical Industries' Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #80 out of 979 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Teva Pharmaceutical Industries' Piotroski F-Score too high?
Teva Pharmaceutical Industries' current Piotroski F-Score of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Teva Pharmaceutical Industries' value of 7 is 40% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #80 out of 979 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Teva Pharmaceutical Industries has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #80 out of 979 companies for Piotroski F-Score. This places Teva Pharmaceutical Industries in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Teva Pharmaceutical Industries' value of 7 is 40% above this benchmark. Historically, Teva Pharmaceutical Industries' own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Teva Pharmaceutical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current Piotroski F-Score is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Teva Pharmaceutical Industries (BSP:T1EV34) has a current Piotroski F-Score of 7. The stock's GF Value™ is R$53.85, compared to a current price of R$85.99 — trading 59.7% above its estimated fair value. The current Piotroski F-Score is 7, which is 40% above median its 10-year median of 5.00 and 40% above the Drug Manufacturers industry median of 5.00. Teva Pharmaceutical Industries' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current Piotroski F-Score is 7 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of R$85.99 is trading 59.7% above its estimated GF Value™ of R$53.85.

Key valuation signals for BSP:T1EV34:

  • Piotroski F-Score: 7 (40% above median its 10-year median of 5.00)
  • GF Value™: R$53.85 vs. price of R$85.99 (59.7% above fair value)
  • GF Score™: 60/100 with 4 warning signs
  • Industry Position: 40% above the Drug Manufacturers median (#80 of 979)

No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
60GF Score

Get the complete analysis for BSP:T1EV34

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$85.99
Price
R$53.85
GF Value